Overview

Gender

female

Dr. Warrington has more than seventeen years of experience in genetics, biotechnology and molecular diagnostics, with a primary focus of moving new technologies and applications into clinical practice.

Working with Affymetrix Inc. from the ground up, Dr. Warringotn helped build the company from a small start-up to a multi-billion dollar market cap corporation.

Dr. Warrington wore multiple hats as Vice President of Research and Development for Emerging Markets and Molecular Diagnostics.

In partnership with Roche Molecular Systems and was the originator and lead scientist for the first FDA cleared microarray system for a diagnostic test.


Dr. Warrington's work has resulted in over 50 publications and 15 patents. Additionally, Dr. Warrington has made substantial contributions to advancing the development of clinical applications of diagnostic tests.

Dr. Warrington is driving the establishment of standard controls and best practices and currently serves as a member of the Clinical and Laboratory Standards Institute (CLSI), Molecular Methods Area Committee.

As the founder and chairholder of the External RNA Controls Consortium (ERCC), she led an international group of scientists from both public and private sectors to establish the first panel of nucleic acid Standard Reference Material at the National Institute of Standards and Technology (NIST).

Dr. Warrington has also had the privilege of serving as a member of the Personalized Healthcare Working Group, American Health Information Community (AHIC), U.S. Department of Health and Human Services (HHS) as well as chairing the Subcommittees on Genetic and Genomic Tests and Pharmacogenomics.

Additionally, she has served as a business and industry council (BIAC) member to the Organization of Economic Cooperation and Development (OECD) Biotechnology Working Group.